Article
Controversies and dilemmas in allogeneic transplantation for myelofibrosis.
Best practice & research. Clinical haematology - 1 Jun 2014
Shanavas Mohamed, Gupta Vikas
Abstract excerpt
JAK1/2 inhibitors have broadened the therapeutic options in myelofibrosis. Though not curative, they result in a meaningful clinical benefit with relatively fewer side effects. In contrast, allogeneic hematopoietic cell transplantation (HCT) is a potentially curative option, but is associated with significant morbidity and mortality. Hence, an important question is the optimal timing of HCT in the era of JAK...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.